Azathioprine and 6-Mercaptopurine use in the Swiss IBD cohort : adverse effects, causes of discontinuation and risk of "flares" according to 6-TG levels

Details

Ressource 1Download: BIB_0CE49558DEF8.P001.pdf (566.55 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_0CE49558DEF8
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Poster: Summary – with images – on one page of the results of a researche project. The summaries of the poster must be entered in "Abstract" and not "Poster".
Collection
Publications
Title
Azathioprine and 6-Mercaptopurine use in the Swiss IBD cohort : adverse effects, causes of discontinuation and risk of "flares" according to 6-TG levels
Title of the conference
Journal of Crohn's & Colitis ; vol. 9 supl. 1
Author(s)
Lavrek D., Fournier N., Pittet V., Muller D., Mottet C.
Organization
10th Congress of ECCO - Crohns & Colitis Organisation : Inflammatory bowel diseases. 18-21 February 2015, Barcelona, Spain
ISBN
1873-9946
Publication state
Published
Issued date
2015
Peer-reviewed
Oui
Volume
9
Pages
S272-S272
Language
english
Notes
Poster Presentation P385
Abstract
Background: To characterize and analyze in the Swiss IBD Cohort: a) reported Azathioprine (AZA) and 6-Mercaptopurine (6-MP) adverse effects (AE), b) causes of discontinuation and c) response to therapy according to gastroenterologists' clinical judgment, d) whether level of 6-TGN < 235pmol/8 x108 red blood cells (RBC) is associated with a higher risk of "flare" occurrence.
Methods: Retrospective statistical description, Cox model and Kaplan-Meier survival estimation.
Results: 1499 patients with Crohn's Disease (CD) and 1066 with Ulcerative colitis (UC).
Web of science
Create date
12/06/2015 10:39
Last modification date
20/08/2019 12:34
Usage data